Alyeska Investment Group L.P. Grows Position in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Alyeska Investment Group L.P. increased its stake in Ultragenyx Pharmaceutical Inc. by 3.9%, owning approximately 1.58% of the company worth $54.1 million after acquiring an additional 55,611 shares.
• Ultragenyx Pharmaceutical reported a 13.2% increase in year-over-year revenue, totaling $166.5 million, with earnings per share of ($1.17) beating estimates by $0.10.
• In analyst coverage, William Blair began with an "outperform" rating and a target price of $65.00, while several other firms adjusted their price targets downwards, impacting overall sentiment.

Alyeska Investment Group L.P. raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,495,351 shares of the biopharmaceutical company's stock after buying an additional 55,611 shares during the quarter. Alyeska Investment Group L.P. owned about 1.58% of Ultragenyx Pharmaceutical worth $54,147,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 323 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth approximately $57,000. Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter worth approximately $59,000. Covestor Ltd boosted its holdings in shares of Ultragenyx Pharmaceutical by 86.8% in the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after purchasing an additional 795 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter worth approximately $82,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Down 1.5%

RARE opened at $31.55 on Thursday. The business has a fifty day moving average of $30.61 and a 200 day moving average of $35.02. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37. The stock has a market cap of $3.04 billion, a P/E ratio of -5.71 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.Ultragenyx Pharmaceutical's revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on RARE shares. William Blair started coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price for the company. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a report on Thursday, July 10th. Wedbush dropped their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Canaccord Genuity Group dropped their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a report on Monday, July 28th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.